Edwards Lifesciences Corporation (EW) Stock

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Edwards Lifesciences Corporation is led by CEO Bernard J. Zovighian, employs 15,800 people, headquartered in Irvine, US, publicly traded since 2000.

Edwards Lifesciences Corporation (EW) stock trades at $85.76 with a market capitalization of $49.38B. The stock is valued at a price-to-earnings (P/E) ratio of 43.22, price-to-book of 4.49, price-to-sales of 8.09. Over the past 52 weeks the stock has ranged between $69.21 and $95.86, and currently trades 10.5% below its 52-week high.

On profitability, Edwards Lifesciences Corporation generates a return on equity (ROE) of 10.39%, return on capital employed of 15.83%, an operating margin of 26.96%, a net profit margin of 17.34%.

In its most recent fiscal year, Edwards Lifesciences Corporation reported annual revenue of $6.1B, net profit of $1.1B, revenue has compounded at 6.7% a year over the last five years, profit at 5.5% a year.

The balance sheet shows a debt-to-equity ratio of 0.07 — a conservative balance sheet with little leverage risk, a current ratio of 3.71, total assets of $13.7B, $2.9B in cash and equivalents.

EW has an average daily trading volume of 5,114,130 shares, a beta of 0.87.

Official website: www.edwards.com